Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07827469 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tofacitinib in the Treatment of IgG4 Related Diseases

Name: Tofacitinib in the Treatment of IgG4 Related Diseases — clinical trial record (NCT07827469)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusCompleted

PhaseNot applicable

SponsorPeking University People's Hospital

Started2023-04-01

View on ClinicalTrials.gov ↗

Peking University People's Hospital

220 trials monitored

See 6 trials at risk

This study is a single centre, open label, randomized controlled study to compare the efficacy and safety between steroids plus tofacitinib and steroids alone in active IgG4-related diseases patients. It is expected to enroll a total of 58 IgG4 RD patients. The sample size of two groups is 1:1. The primary end points of this study is to compare the IgG4-RD response rate between two groups at 24 weeks.

Trial Details

NCT Number	NCT07827469
Lead Sponsor	Peking University People's Hospital
Conditions	Immunoglobulin G4-Related Disease, Janus Kinase Inhibitors
Enrollment	58 participants
Start Date	2023-04-01
Primary Completion	2026-06-03 (estimated)
Study Completion	2026-06-03 (estimated)
Updated on ClinicalTrials.gov	2026-09-18